Surrey Heartlands

Joint Formulary & PAD

Ibandronic acid - Malignancy

You are here : Home > Formulary Search > Ibandronic acid - Malignancy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important

50mg tablets for bone metastases in breast cancer. Specialist initiation and prescribing for at least 1 month before any request is made for primary care prescribing.

 

Status 2

Red
Formulations :
  • Intravenous infusion
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important

Used in

  • hypercalcaemia of malignancy
  • bone metastases
  • prevention of skeletal events

Documentation

Shared Care
Bondronate For the prevention of skeletal events in metastatic breast cancer - Amber* information sh
Shared Care
Bondronat for the prevention of skeletal events in Metastatic Breast Cancer - RSCH Amber* informatio
Shared Care
Ibandronic Acid (Bondronat) in Breast Cancer - South West London Shared Care - January 2014

PAD Profile

ChemicalSubstance :
Ibandronic acid
Indication :
Malignancy
Group Name :
Keywords :
Hypercalcaemia of malignancy, Bone metastases, Prevention of skeletal events
Brand Names Include :
Bondronat
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Ibandronic acid is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Malignancy.

Committee Recommendations (0)

  • No records returned.